Life Sciences Tools and Services
Company Overview of SomaLogic, Inc.
SomaLogic, Inc. discovers, develops, and commercializes life science research tools and clinical diagnostic products for biological and medical science applications. It offers SOMAMER REAGENT, a proteomic platform that combines the properties of antibodies and aptamers; and SOMAscan assay, a protein biomarker discovery and development tool for protein measurement solutions. The company also provides diagnostic tests for various diseases and conditions. In addition, it offers protein-measurement assays, kits, and reagents for life science and biopharma researchers. Further, the company also provides protein biomarker-based diagnostics; and chemical reagents as potential therapeutic molecules....
2945 Wilderness Place
Boulder, CO 80301
Founded in 1999
Key Executives for SomaLogic, Inc.
Chief Executive Officer and Director
Founder and Chairman of the Board
Chief Medical Officer Emertius
Compensation as of Fiscal Year 2015.
SomaLogic, Inc. Key Developments
SomaLogic, Inc. Presents at Canaccord Genuity 2015 Medical Technology & Diagnostics Forum, Nov-19-2015 09:40 AM
Oct 31 15
SomaLogic, Inc. Presents at Canaccord Genuity 2015 Medical Technology & Diagnostics Forum, Nov-19-2015 09:40 AM. Venue: Westin Grand Central, New York, New York, United States.
SomaLogic, Inc. Presents at BIO-Europe 2015, Nov-03-2015 02:00 PM
Sep 21 15
SomaLogic, Inc. Presents at BIO-Europe 2015, Nov-03-2015 02:00 PM. Venue: Munich, Germany.
SomaLogic and Otsuka Pharmaceutical Extends Initial Collaboration Agreement to Continue the Development of Several Somamer Therapeutics
Aug 11 15
SomaLogic announced that Otsuka Pharmaceutical has extended its initial collaboration agreement with SomaLogic to continue the development of several SOMAmer therapeutics. Specific projects and financial terms in the extended agreement were not disclosed. SomaLogic is the recognized leader in the development and application of advanced aptamer technologies. The company has designed its proprietary SOMAmer reagents to combine the wide target range of antibodies with the consistency and reproducibility of traditional aptamers. The chemical addition of protein-like side chains to the nucleic acid bases that comprise a SOMAmer molecule results in the ability to discover molecules that bind specifically and tightly to virtually any targeted protein. These properties allow SOMAmer molecules to be used in virtually any laboratory or clinical application that currently uses monoclonal antibodies, including therapeutics. This property, along with other unique characteristics, makes SOMAmer candidates attractive for novel therapeutic discovery and development.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries